Key facts
- This page summarizes Freebird Partners LP's Form 4 filing for Comera Life Sciences Holdings, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Jan 2024, 20:09.
Freebird Partners LP - 29 Dec 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 29 Dec 2023
- Net transaction value
- +$134,950
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2024, 20:09:49 UTC
- Prior SEC filing
- 18 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- Freebird Partners LP, By: Freebird Investments LLC, its general partner, By: /s/ Curtis W. Huff, Chairman and President
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Freebird Partners LP filed Form 4 for Comera Life Sciences Holdings, Inc. on 03 Jan 2024.
Change
- Previous filing in this sequence was filed on 18 Dec 2023.
- Current net transaction value: +$134,950.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CMRA
transaction
Derivative
Convertible Note Shares
Purchase
- Transaction value
- $134,950
- Shares
- +2,453,636
- Change %
- Price
- $0.0550
- Shares after
- 2,453,636
- Date
- 29 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001 per share
- Underlying amount
- 2,453,636
- Exercise price
- $0.0550
- Footnotes
- F1, F2, F3
CMRA
transaction
Derivative
Common Stock Purchase Warrant
Purchase
- Transaction value
- Shares
- +4,907,272
- Change %
- +200%
- Price
- Shares after
- 7,362,005
- Date
- 29 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001 per share
- Underlying amount
- 4,907,272
- Exercise price
- $0.0550
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.0001 ("Common Stock") of Comera Life Sciences Holdings, Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.
Footnote F2
Pursuant to that certain Securities Purchase Agreement dated December 29, 2023, as announced in the Issuer's Current Report on Form 8-K filed with the Securities Exchange Commission on December 29, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $134,950, (i) a Senior Convertible Note in the principal amount of $134,950 (the "Note") with a one (1) year term, and (ii) a warrant to purchase up to 4,907,272 shares of Common Stock (the "Warrant" and such transactions the "Transactions").
Footnote F3
(Continued from footnote 2) The Note may be converted at any time and from time to time after December 29, 2023, at the option of the holder, at a conversion price of $0.055 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 29, 2023, and may be exercised through December 29, 2028, at an exercise price of $0.055 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company.